


Company Overview

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.

Our portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

Gilead was founded in 1987 in Foster City, California. Since then, we have grown to become one of the world's largest biopharmaceutical companies, with more than 8,000 employees across six continents.



COMMERCIAL PORTFOLIO

HIV	LIVER	ONCOLOGY	RESPIRATORY
Genvoya® elvitegravir /cobicistat / emtricitabine/tenofovir alafenamide Descovy® emtricitabine / tenofovir alafenamide Truvada® emtricitabine/tenofovir disoproxil fumarate Viread® tenofovir disoproxil fumarate Emtriva® emtricitabine Vitekta® elvitegravir Atripla® efavirenz/emtricitabine/ tenofovir disoproxil fumarate Tybost® cobicistat	Epclusa® sofosbuvir/velpatasvir for Chronic hepatitis C Harvoni® ledipasvir/sofosbuvir for Chronic hepatitis C Sovaldi® sofosbuvir for Chronic hepatitis C Viread® tenofovir disoproxil fumarate for Chronic hepatitis B Hepsera® adefovir dipivoxil for Chronic hepatitis B	Zydelig® idelalisib for Chronic lymphocytic leukemia, Follicular lymphoma, and Small lymphocytic lymphoma Letairis® ambrisentan for Pulmonary arterial hypertension Ranexa® ranolazine for Chronic angina Lexiscan® regadenoson injection for Coronary vasodilatation	Cayston® aztreonam for Cystic fibrosis Tamiflu® oseltamivir phosphate for Influenza A and B OTHER AmBisome® amphotericin B liposome for Fungal infections Macugen® pegaptanib sodium for Macular degeneration

Images shown do not represent actual size.

Second Quarter 2016 Financial Highlights

- ▶ Total revenues for the second quarter of 2016 decreased 6% to \$7.8 billion from \$8.2 billion for the second quarter of 2015.
- ▶ Non-GAAP net income for the second quarter of 2016, which excludes amounts related to acquisition, stock-based compensation, and other was \$4.2 billion, or \$3.08 per diluted share compared to \$4.8 billion, or \$3.15 per diluted share for the second quarter of 2015
- ▶ Product sales decreased 6% to \$7.7 billion for the second quarter of 2016 compared to \$8.1 billion for the second quarter of 2015.
- ▶ As of June 30, 2016, Gilead had \$24.6 billion of cash, cash equivalents and marketable securities compared to \$21.3 billion as of March 31, 2016.
- ▶ During the second quarter of 2016, Gilead generated \$4.9 billion in operating cash flow.

